Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Trends in the treatment of localized prostate cancer using supplemented cancer registry data.

Hamilton AS, Albertsen PC, Johnson TK, Hoffman R, Morrell D, Deapen D, Penson DF.

BJU Int. 2011 Feb;107(4):576-84. doi: 10.1111/j.1464-410X.2010.09514.x. Epub 2010 Aug 24.

2.

A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age.

Terakedis BE, Rossi PJ, Liauw SL, Johnstone PA, Jani AB.

Am J Clin Oncol. 2010 Dec;33(6):619-23. doi: 10.1097/COC.0b013e3181c4c6e1.

PMID:
20051808
3.

Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.

Underwood W 3rd, Jackson J, Wei JT, Dunn R, Baker E, Demonner S, Wood DP.

Cancer. 2005 Feb 1;103(3):538-45.

4.

Re: Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer.

Lee CT.

J Natl Cancer Inst. 2004 May 5;96(9):718-9. No abstract available.

PMID:
15126615
5.

Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.

Shavers VL, Brown M, Klabunde CN, Potosky AL, Davis W, Moul J, Fahey A.

Med Care. 2004 Mar;42(3):239-50.

PMID:
15076823
6.

Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer.

Godley PA, Schenck AP, Amamoo MA, Schoenbach VJ, Peacock S, Manning M, Symons M, Talcott JA.

J Natl Cancer Inst. 2003 Nov 19;95(22):1702-10.

PMID:
14625261
7.

A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006.

Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, Shariat SF, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI.

Eur Urol. 2011 Jan;59(1):88-95. doi: 10.1016/j.eururo.2010.10.003. Epub 2010 Oct 14.

PMID:
20965646
8.

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS.

J Natl Cancer Inst. 1999 Jun 16;91(12):1017-24.

PMID:
10379964
9.

Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration.

Wood HM, Reuther AM, Gilligan TD, Kupelian PA, Modlin CS Jr, Klein EA.

J Urol. 2007 Oct;178(4 Pt 1):1271-6. Epub 2007 Aug 14.

PMID:
17698101
11.

Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis.

Powell IJ, Dey J, Dudley A, Pontes JE, Cher ML, Sakr W, Grignon DJ, Wood DP.

Urology. 2002 Jun;59(6):907-12.

PMID:
12031379
12.

The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.

Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, Aronson WJ, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Fox S.

Contemp Clin Trials. 2009 Jan;30(1):81-7. doi: 10.1016/j.cct.2008.08.002. Epub 2008 Aug 23.

PMID:
18783735
13.

Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999.

Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF.

Urology. 2004 Dec;64(6):1171-6.

PMID:
15596192
14.

Genetics, disparities, and prostate cancer.

Rebbeck TR.

LDI Issue Brief. 2005 May-Jun;10(7):1-4.

PMID:
16114130
15.

The lifetime risk of developing prostate cancer in white and black men.

Merrill RM, Weed DL, Feuer EJ.

Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):763-8.

17.

Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.

Nieder AM, Porter MP, Soloway MS.

J Urol. 2008 Nov;180(5):2005-9; discussion 2009-10. doi: 10.1016/j.juro.2008.07.038. Epub 2008 Sep 17.

PMID:
18801517
18.

Changing trends in U.S. prostate cancer incidence rates.

Merrill RM, Potosky AL, Feuer EJ.

J Natl Cancer Inst. 1996 Nov 20;88(22):1683-5. No abstract available.

PMID:
8931614
19.

Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses.

Lee LN, Barnswell C, Torre T, Fearn P, Kattan M, Potters L.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):282-9.

PMID:
12023131
20.

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA Jr, Thompson IM.

J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83. Epub 2007 Sep 11.

PMID:
17848673

Supplemental Content

Support Center